Pathway · Read the evidence

Give the claim a proper check.

Ask what the evidence actually covers: the person, the pharmacy, the product or a particular use. Those are different questions.

Match the claim to the right record

A license checks the person or business
An active license gives no rating of the care’s quality.
An approval concerns a particular medicine
FDA stands for Food and Drug Administration, a U.S. agency.
It reviews a particular medicine and the health problem it is meant to treat.
Calling a medicine a peptide does not mean the FDA has approved it.
Being registered does not mean being approved
As of September 2026, a place that makes or handles medicines can be registered with the FDA without being FDA-approved.
Putting a medicine on an FDA list does not give the medicine approval either.
A drug number helps you find its listing
NDC is a common abbreviation for National Drug Code, a number that helps you find a product in the FDA’s drug list.
As of September 2026, that number or listing did not prove the FDA had approved the product or checked the information.
A problem report calls for a closer look
An FDA report does not prove that a medicine caused a problem or show how often that problem happens.

Compounding is the name for preparing a medicine to order.

As of September 2026, compounded drugs lacked FDA approval; the FDA had not checked their quality, benefit or safety before marketing.

The substance called BPC-157 is a peptide; no medicine containing it had United States approval as of September 2026.

If someone offers it to you, ask which health problem they say it will treat.

A lack of drug approval does not, by itself, answer whether a pharmacy may use an ingredient.

A pharmacy making medicine for one patient must check that each raw ingredient is allowed.

To qualify, the ingredient must meet official quality rules, be part of an approved medicine, or be listed by the FDA as an allowed ingredient.

BPC-157 met none of those ingredient conditions in the FDA documents checked in September 2026.

Ask the pharmacist which ingredient rule they are relying on for the exact medicine offered to you.

The FDA’s allowed-ingredient list is one way a raw ingredient can qualify for use in medicine made for one patient.

As of September 2026, a panel advising the FDA could not change that list just by voting.

The FDA must publish a proposed rule, let the public comment and finish its review before changing the list.

The July 2026 meeting discussed adding seven peptides, including BPC-157, to that list.

No FDA vote record was published by September 2026, but HHS’s October 30, 2026 draft reports the July panel’s vote in favor of adding BPC-157.

A headline about that vote does not show that a pharmacy may now use BPC-157.

Get the complete product name
A broad treatment name makes it hard to check a claim about a medicine. Get the medicine’s precise name and ask which form you would receive: a pill, a shot or something else.
Ask what use is being supported
Which claim about my condition does this source support?
Ask what remains uncertain
What does this record leave unanswered about the medicine or the treatment plan?
Check the date
Look for the date of the information you are being given, especially when the claim concerns rules or an offer.

Endnotes for this chapter

What the FDA approves
Use this explanation to separate product approval from registration.
Read the official source
What a drug number means
The FDA explains why a drug number or listing does not prove approval.
Read the official source
FDA approval records
These government records let you check a drug’s approval history.
Read the official source
Compounded medicines and FDA review
The FDA explains what its review does not cover for compounded drugs.
Read the official source
How the allowed-ingredient list changes
This FDA page explains how it changes the list of raw ingredients allowed for medicine made for one patient.
Read the official source